Phase II study of irinotecan (CPT-11) in patients with advanced colorectal cancer resistant to 5-fluorouracil based chemotherapy.

被引：0
|
作者：
Salinas, P
Lara, MA
de Septién, CFM
Feliu, J
Espinosa, E
de Castro, J
García-Girón, C
机构：
[1] Hosp Gen Yague, Burgos, Spain
[2] Hosp La Paz, Madrid, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [21] The current chemotherapy for advanced pancreatic cancer including the result of phase II study of irinotecan (CPT-11)
    Sumii, Toshihiko
    Fujimori, Nao
    Funakoshi, Akihiro
    PANCREAS, 2008, 37 (01) : 112 - 112
  • [22] Phase II study of metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with refractory metastatic colorectal cancer (MCRC).
    Moiseyenko, V.
    Chubenko, V.
    Protsenko, S.
    Mikhalichenko, T.
    Moiseyenko, F.
    Brezhnev, N.
    Moiseyenko, A.
    Kornilov, A.
    Zueva, E.
    Gorchakova, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer
    J. Cassinello
    P. López-Alvarez
    A. Martínez-Guisado
    M. Valladares
    G. Huidobro
    R. López
    U. Bohn
    I. Sevilla
    P. Ballesteros
    M. Jorge
    R. Pérez-Carrión
    J. L. Fernández
    J. Dorta
    Medical Oncology, 2003, 20 : 37 - 43
  • [24] Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer
    Cassinello, J
    López-Alvarez, P
    Martínez-Guisado, A
    Valladares, M
    Huidobro, G
    López, R
    Bohn, U
    Sevilla, I
    Ballesteros, P
    Jorge, M
    Pérez-Carrión, R
    Fernández, JL
    Dorta, J
    MEDICAL ONCOLOGY, 2003, 20 (01) : 37 - 43
  • [25] A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
    Oliver F Bathe
    Scott Ernst
    Francis R Sutherland
    Elijah Dixon
    Charles Butts
    David Bigam
    David Holland
    Geoffrey A Porter
    Jennifer Koppel
    Scot Dowden
    BMC Cancer, 9
  • [26] Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX
    F Recchia
    G Saggio
    A Nuzzo
    A Lalli
    L Di Lullo
    A Cesta
    S Rea
    British Journal of Cancer, 2004, 91 : 1442 - 1446
  • [27] Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX
    Recchia, F
    Saggio, G
    Nuzzo, A
    Lalli, A
    Di Lullo, L
    Cesta, A
    Rea, S
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1442 - 1446
  • [28] 5-fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomised phase II study of the Southern Italy Oncology Group
    Maiello, E
    Gebbia, V
    Giuliani, F
    Paoletti, G
    Gebbia, N
    Cigolari, S
    Fortunato, S
    Pedicini, T
    Borsellino, N
    Lopez, M
    Colucci, G
    ANNALS OF ONCOLOGY, 2000, 11 (08) : 1045 - 1051
  • [29] A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer
    Kakolyris, S
    Souglakos, J
    Kouroussis, C
    Androulakis, N
    Mavroudis, D
    Kalbakis, K
    Kotsakis, A
    Vardakis, N
    Koukourakis, M
    Romanos, J
    Georgoulias, V
    ONCOLOGY, 2001, 60 (03) : 207 - 213
  • [30] A multicenter phase II study of irinotecan (CPT-11) and bolus 5-fluorouracil (5FU)/I-leucovorin (I-LV) in patients with metastatic colorectal cancer
    Fujishima, H
    Makiyama, A
    Miyanaga, O
    Ueda, A
    Esaki, T
    Mitsugi, K
    Baba, E
    Kusaba, H
    Harada, M
    Nakano, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 306S - 306S
12345